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ABSTRACT
Background The prevalence of diseases other than 
TB detected during chest X- ray (CXR) screening is 
unknown in sub- Saharan Africa. This represents a missed 
opportunity for identification and treatment of potentially 
significant disease. Our aim was to describe and quantify 
non- TB abnormalities identified by TB- focused CXR 
screening during the 2016 Kenya National TB Prevalence 
Survey.
Methods We reviewed a random sample of 1140 adult 
(≥15 years) CXRs classified as ’abnormal, suggestive 
of TB’ or ’abnormal other’ during field interpretation 
from the TB prevalence survey. Each image was read 
(blinded to field classification and study radiologist 
read) by two expert radiologists, with images classified 
into one of four major anatomical categories and 
primary radiological findings. A third reader resolved 
discrepancies. Prevalence and 95% CIs of abnormalities 
diagnosis were estimated.
Findings Cardiomegaly was the most common non- 
TB abnormality at 259 out of 1123 (23.1%, 95% CI 
20.6% to 25.6%), while cardiomegaly with features of 
cardiac failure occurred in 17 out of 1123 (1.5%, 95% 
CI 0.9% to 2.4%). We also identified chronic pulmonary 
pathology including suspected COPD in 3.2% (95% CI 
2.3% to 4.4%) and non- specific patterns in 4.6% (95% 
CI 3.5% to 6.0%). Prevalence of active- TB and severe 
post- TB lung changes was 3.6% (95% CI 2.6% to 4.8%) 
and 1.4% (95% CI 0.8% to 2.3%), respectively.
Interpretation Based on radiological findings, we 
identified a wide variety of non- TB abnormalities during 
population- based TB screening. TB prevalence surveys 
and active case finding activities using mass CXR offer 
an opportunity to integrate disease screening efforts.
Funding National Institute for Health Research 
(IMPALA- grant reference 16/136/35).
INTRODUCTION
TB remains the leading adult infectious killer in the 
world.1 Despite an estimated nine per cent relative 
increase in case detection in 2018, there are still 
three million (30%) people with TB who are undiag-
nosed or not reported to national TB programmes.1 
In an effort to identify missing people with TB, 
countries have adopted more sensitive diagnostic 
tools, including Xpert MTB/RIF, scaled up inten-
sified active case finding (ACF), and adapted their 
screening and diagnostic algorithms to include 
chest X- ray (CXR) as a sensitive and efficient high- 
throughput initial screening test.2
Historically, miniature radiography for mass 
TB screening activities was widely used in high- 
income countries throughout the 20th century.3–6 
In lower- income and middle- income countries 
(LMICs), however, CXR has been used primarily 
as a complementary tool to support clinical diag-
nosis of patients who are sputum smear negative.7 
Following the findings from national TB prevalence 
surveys that have employed CXR for screening, 
there is a renewed interest in the utility of CXR 
for TB screening, and to triage people seeking care 
with symptoms for further TB investigations.8–10 
In TB prevalence surveys conducted in LMICs, 
CXR has shown high sensitivity for pulmonary 
TB (PTB) (94%, 95% CI 88% to 98%) but poor 
specificity (73%, 95% CI 68% to 77%), necessi-
tating confirmation with a microbiological test.11–13 
Mathematical modelling of various TB screening 
algorithms, as well as diagnostic algorithms, shows 
that CXR followed by Xpert MTB/RIF, though 
Key messages
What is the key question?
 ► What was the prevalence of non- TB findings 
when chest X- rays (CXRs) were used in the 
2016 Kenya National TB Prevalence Survey?
What is the bottom line?
 ► There was a high prevalence of cardiomegaly, 
chronic pulmonary diseases, post- TB lung 
disease and non- specific lung diseases; 
implementation of CXR TB screening in lower- 
income and middle- income countries offers 
an opportunity to integrate disease screening 
efforts.
Why read on?
 ► To our knowledge, this is the first study in 
sub- Saharan Africa to describe and quantify 
non- TB CXR findings among participants 
who underwent mass screening as part of a 
population- based TB prevalence survey and has 
important health policy implications.
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resource intensive, has the lowest number needed to screen to 
identify a case.14 Increased digital CXR availability, coupled with 
the development of computer aided detection (CAD) software 
for identification of TB, has enabled increasing use of CXR in 
screening for TB in areas with limited access to radiologists or 
expert clinicians.15 16
Use of CXR for mass TB screening will identify other condi-
tions, especially those related to complications of a rising burden 
of non- communicable diseases (NCDs) in LMICs, including 
cardiovascular disease, chronic respiratory disease and cancer.17 
A short narrative report from Europe in the 1940s highlighted 
a significant number of 1225 out of 3423 (35.7%) of non- TB 
findings in mass radiography screening.5 However, there is no 
contemporaneous evidence about the prevalence of non- TB 
abnormalities identified during TB prevalence surveys and mass 
radiographic TB screening interventions. TB prevalence surveys 
focus on accurate estimation of TB prevalence encouraging 
readers to prioritise sensitivity over specificity and include any 
CXR abnormalities to identify participants eligible for TB bacte-
riological testing.9
Systematic screening/ACF programmes also focus on early 
detection of active TB.4 CAD software for TB) demonstrates 
high sensitivity for CXR TB diagnosis but is not calibrated for 
detection of non- TB abnormalities.18 Countries are currently 
adopting CXR screening in combination with CAD software 
systems, both for mass community TB screening activities and 
in healthcare settings.16 However, the burden of non- TB CXR 
abnormalities during these mass screening activities is unknown.
We set out to describe and quantify the nature of non- TB 
abnormalities on abnormal CXRs taken during the 2016 Kenya 
National TB Prevalence Survey.13 We hypothesised that the 
use of CXR during TB screening would identify a substantial 




We conducted a secondary retrospective analysis on cross- 
sectional study data13 using individual- level participant CXR 
data from adult community members who took part in the 2016 
Kenya National TB Prevalence Survey.13 The study was in two 
parts: an initial pilot study (n=484) to refine tools and estimate 
the full sample size required for precision and the main study 
(n=1140). The main aim was to estimate prevalence and uncer-
tainty for CXR- identified non- TB disease pathology within this 
population.
Study population
The prevalence survey (reported elsewhere)12 13 was a population- 
based cross- sectional study conducted in 2015–2016. The aim 
was to determine the prevalence of bacteriologically confirmed 
PTB among adults (≥15 years) and to assess health- seeking 
behaviour. The survey used the WHO recommended screening 
strategy comprising symptom questionnaire and CXR.9 There 
were 63 050 enrolled participants, 62 484 (99%) underwent 
CXR screening. The survey identified 305 TB cases; weighted 
national prevalence of 558 (95% CI 455 to 662) per 100 000 
adult population.12 13
Methods
Classification of CXRs during the Kenya TB Prevalence Survey
Digitally acquired posterior- anterior CXRs were uploaded to a 
digital archive. Independent, blinded reading of each film was 
conducted by two clinical officers in the field who had undergone 
CXR training. Each image was classified as either (1) normal; 
(2) ‘abnormal, suggestive of TB’; or (3) ‘abnormal other’. Any 
participant with a CXR classified as ‘abnormal, suggestive of TB’ 
by either one of the clinical officers, or with a cough of more than 
2 weeks, was eligible for sputum collection. Those confirmed to 
have TB were referred for treatment and those with other CXR 
abnormalities were to be linked to a health facility. The preva-
lence survey has been reported fully elsewhere.13
Study procedures
We obtained an anonymised line list of all the participants from 
the prevalence survey database; our sampling frame included all 
CXRs classified as ‘abnormal, suggestive of TB’ or ‘abnormal 
other’ by the survey field readers. Images selected for inclusion 
in this study were uploaded to a web- based picture archiving and 
communication system.
Ten specialist radiologists (five Kenyan, five from the UK) with 
median experience of 12.5 years in TB/chest radiology were 
recruited (online supplemental appendix 1). One- to- one training 
of the radiologists was provided on the online reporting tool and 
diagnostic case definitions.19 Based on previous reporting tools, 
we developed radiological definitions, comprised of abnormali-
ties within four major anatomical areas (lung parenchyma, heart 
and great vessels, pleura and mediastinum).20 For each major 
anatomical area, a list of most common radiological diagnoses 
was developed, taking into consideration Kenyan disease epide-
miology (online supplemental appendix 2). Radiologists were 
able to select one primary diagnosis. Differential diagnoses could 
be added where a single, confident primary diagnosis could not 
be made.
Each radiologist was randomly assigned CXRs for review. 
After completion of each reading, the image was released into 
a pool for second reading. The readers were blinded to each 
other’s report, but not to clinical information (sex, age, HIV 
status and symptoms). Finally, 10% of images were reallocated 
to the original readers for assessment of intraobserver variation. 
Where pairs of radiologists had discrepant primary diagnoses, 
one of two additional radiologists undertook a consensus read, 
with knowledge of the first two radiologists’ classification.
Data management and analysis
Based on the pilot study findings (online supplemental appendix 
3), 1140 CXR images (390 ‘abnormal, suggestive of TB’ and 
750 ‘abnormal other’) would be required to estimate the preva-
lence of old/latent TB and cardiomegaly (the most common find-
ings in the pilot study in the respective categories) within 3.5% 
percentage points of the true value with 95% confidence.
For the main study, we included images classified as either 
‘abnormal, suggestive of TB’ and ‘abnormal other’, excluding 
those sampled in the pilot study. These images were grouped 
into 99 strata as per the prevalence survey clusters, and sampled 
without replacement from each stratum. Statistical analysis used 
R V.3.6.2 (The R Foundation for Statistical Computing, Vienna, 
Austria). Inter- reader and intrareader agreement was calculated 
using the Cohen’s Kappa statistic. Study participant characteris-
tics were calculated as medians or percentages. The prevalence 
of primary diagnoses was calculated as the number of CXRs 
depicting the abnormality divided by the total number of images 
that were readable; 95% CIs were estimated using the binomial 
exact method. A number of final diagnoses were combined or 
removed before analysis, based on their prevalence and likeli-
hood of clinical relevance.
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Out of 63 050 participants in the prevalence survey, 62 484 
(99%) underwent CXR, with 50 935 (81.5%) reported as normal 
by survey field staff, 6425 (10.3%) as ‘abnormal, suggestive of 
TB’ and 5124 (8.2%) as ‘abnormal other’ (figure 1).
Participant characteristics
Out of 1140 images included in the main study, 1123 (98.5%) 
were read by two radiologists and 17 (1.5%) were classified as 
unreadable. The median patient age was 51.0 years (IQR 36.5–
66.0) and 720 (64.2%) were female. Two hundred and fifty 
(22.3%) had reported cough of any duration, 40 (3.6%) chest 
pain and 42 (3.7%) self- reported HIV- positive status. Six (0.5%) 
reported current and 34 (3.0%) reported previous TB treatment. 
GeneXpert and/or culture results were positive for 27 out of 456 
(5.9%) of those that had sputum tested (table 1).
Inter-reader and intrareader variability
The overall agreement between pairs of readers was moderate 
with kappa=0.41 (online supplemental appendix 4). There was 
perfect intrareader agreement at kappa=1. The median time 
between intraobserver reliability assessments was 22 days.
Prevalence of CXR abnormalities
Overall, six hundred (53.4%) images were classified by study 
radiologists as having any abnormality. Of the images classi-
fied as ‘abnormal, suggestive of TB’ by field interpretation in 
the survey, 203 (64.9%) were classed by expert reviewers as 
abnormal, whereas among the ‘abnormal other’ category, 397 
(49.0%) were abnormal by expert radiologist read (table 1).
Overall prevalence of abnormalities in the major anatomical 
categories were heart and/or great vessels 26.3% (95% CI 23.7% 
to 28.9%), lung parenchyma 26.1% (95% CI 23.5% to 28.8%), 
pleura 7.6% (95% CI 6.1% to 9.3%) and the mediastinum 3% 
(95% CI 2.1% to 4.2%) (figure 2). Among the 600 abnormal 
images, 21% (127/600) had multiple abnormalities, cardio-
megaly accounted for 259 out of 600, 43.2% (39.2%–47.2%) 
followed by mild/moderate post- TB lung changes at 85 out of 
600, 14.2% (11.5%–17.2%) (figure 3).
Among the potentially relevant non- TB abnormalities, cardio-
megaly was the most prevalent at 23.1% (95% CI 20.6% to 
25.6%), while cardiomegaly combined with features of cardiac 
failure occurred in 1.5% (95% CI 0.9% to 2.4%). Non- specific 
patterns were noted in 4.6% (95% CI 3.5% to 6.0%), while 
suspected COPD, including emphysema, was present in 3.2% 
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram showing participant flow from the Kenya National TB Prevalence 
Survey and this nested chest X- ray (CXR) study.
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(95% CI 2.3% to 4.4%). Mediastinal masses, excluding goitres, 
occurred in 0.8% (95% CI 0.4% to 1.5%).
For presumed TB- related abnormalities, prevalence of minor 
post- TB lung changes, such as old/latent TB involving fewer 
than two lobes of damage/scarring, was 7.6% (95% CI 6.1% to 
9.3%), active TB was 3.6% (95% CI 2.6% to 4.8%) and severe 
post- TB lung changes, that is, bronchiectasis and/or destroyed 
lung, 1.4% (95% CI 0.8% to 2.3%).
Between a quarter and a third of females had cardiomegaly 
(29%). For males, 11.7% had cardiomegaly and 11.2% mild/
moderate post- TB lung changes. History of cough was a common 
feature across all diagnosis types, with 69 out of 250 (27.6%) of 
coughers having cardiomegaly. Out of the 40 participants with 
chest pain, 22.5% (10.8%–38.5%) had cardiomegaly and 20% 
(9.1%–35.6%) had minor post- TB lung changes. Bacteriolog-
ical confirmation of TB was found in all categories of reported 
TB- related lung abnormalities and 4 out 27 (14.8%, 4.2%–
33.7%) of images reported as non- specific patterns (table 2). 
Out of the 34 participants with a history of previous TB treat-
ment, features consistent with minor post- TB lung changes were 
Table 1 Characteristics and sputum microbiology results of study participants, stratified by the original survey classification of the chest X- rays as 
‘abnormal, suggestive of TB’ versus ‘abnormal other’
  
Abnormal, suggestive of TB 
(n=385) Abnormal, other (n=737) Total (n=1123) P value
Sex       <0.001
  Missing 0 1 1
  Female 198 (51.4%) 570 (70.8%) 720 (64.2%)
  Male 187 (48.6%) 239 (29.2%) 402 (35.8%)
Age (years)       <0.001
  Median (Q1, Q3) 45.0 (33.0, 64.0) 54.0 (38.0, 67.0) 51.0 (36.2, 66.0)
Study consensus interpretation       <0.001
  Abnormal CXR 247 (64.2%) 353 (49.0%) 600 (53.4%)
  Normal CXR 138 (35.8%) 384 (52.1%) 522 (46.6%)
  Missing     1
Cough of any duration       0.002
  Missing 0 1 1
  No 278 (72.2%) 594 (80.6%) 872 (77.7%)
  Yes 107 (27.8%) 143 (19.4%) 250 (22.3%)
Reported weight loss       0.674
  No 324 (84.2%) 613 (83.2%) 937 (83.5%)
  Yes 61 (15.8%) 124 (16.8%) 185 (16.5%)
Reported fever       0.385
  No 320 (83.1%) 597 (81.0%) 917 (81.7%)
  Yes 65 (16.9%) 140 (19.0%) 205 (18.3%)
Reported night sweats       0.001
  No 278 (72.2%) 594 (80.6%) 872 (77.7%)
  Yes 107 (27.8%) 143 (19.4%) 250 (22.3%)
Self- reported HIV status       0.005
  Missing 183 389 572
  HIV- negative 180 (89.1%) 328 (94.3%) 508 (92.4%)
  HIV- positive 22 (10.9%) 20 (5.7%) 42 (7.6%)
Taking TB treatment       0.069
  Missing 182 340 522
  No 199 (98.0%) 395 (99.5%) 594 (99.0%)
  Yes 4 (2.0%) 2 (0.5%) 6 (1.0%)
Previously treated for TB       <0.001
  Missing 182 403 522
  No 175 (86.2%) 391 (98.5%) 566 (94.3%)
  Yes 28 (13.8%) 6 (1.5%) 34 (5.7%)
Sputum Xpert/culture result       0.001
  Missing 66 600 666
  Negative 293 (91.8%) 185 (99.3%) 429 (94.1%)
  Positive 26 (8.2%) 1 (0.7%) 27 (5.9%)
CXR, chest X- ray.
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reported in 11 (32.4%, 95% CI 17.4% to 50.5%), active PTB 
in 6 (17.6%, 95% CI 6.8% to 34.5%) and severe post- TB lung 
changes in 4 (11.8%, 95% CI 3.3% to 27.5%).
DISCUSSION
The main finding from this analysis of X- ray images from the 
2016 Kenya TB Prevalence Survey was that the use of CXR for 
TB population- based studies identified a large number of patients 
with non- TB- related abnormalities. Cardiac and pulmonary 
diseases accounted for 66% of the non- TB abnormalities in our 
setting. The radiological findings were consistent with compli-
cations of potential underlying NCDs. To our knowledge, this 
is the first study in sub- Saharan Africa to describe and quantify 
non- TB CXR findings among participants who underwent mass 
screening as part of a population- based TB prevalence survey. 
TB prevalence surveys and ACF activities using mass CXR offer 
an opportunity to identify other potential diseases; however, as 
currently structured, when TB is not confirmed, there is limited 
further diagnosis and management of these other conditions.21 
The findings of our study are also timely in the wake of disrup-
tion in the health system caused by COVID-19.22 As countries 
accelerate ACF activities using CXR screening to make up for 
reductions in TB case- notification rates due to COVID-19, they 
could plan systems to manage other findings.
At the outset of the study, we expected abnormalities to be 
primarily related to non- TB pulmonary disease. However, 
the most prevalent findings were cardiac abnormalities with 
cardiomegaly at 23.1% (95% CI 20.6%–25.6%). An outpatient 
Figure 2 Prevalence of abnormalities by major diagnostic categories. PTB, pulmonary TB.
5Mungai BN, et al. Thorax 2021;0:1–8. doi:10.1136/thoraxjnl-2020-216123











research clinic pilot study in The Gambia reports a similar 
finding of cardiac abnormalities being prevalent among patients 
without TB (n=108).21 The prevalence of cardiac abnormalities 
in our study is higher than in The Gambia (26.3% vs 20%).21 
Cardiac abnormality diagnosis in The Gambia was through clin-
ical assessment, ECG and echocardiography (as indicated) versus 
CXR only in our study. This, together with higher median age 
in our study compared with The Gambia (51 years vs 40 years), 
could explain our higher observed prevalence.
Calculation of the cardio- thoracic ratio (CTR) on CXR 
read by humans is a well- described affordable and reproduc-
ible screening method for cardiomegaly.17 23 However, current 
studies, including our own, use CTR cut- off values developed 
in Caucasian populations and there will be a need for robust 
validation of baseline CTR values for healthy populations 
in sub- Saharan Africa.24 CAD for detection of CTR is under 
development.25
In sub- Saharan Africa, the most common causes of cardio-
megaly are conditions of significant public health importance 
associated with premature mortality, including hypertensive 
heart disease, cardiomyopathies, cor pulmonale, chronic rheu-
matic heart diseases and ischaemic heart diseases.23 26 Cardio-
megaly has been associated with both higher body mass index 
and higher median systolic blood pressure.17 The high preva-
lence of cardiomegaly in our study supports exploration of the 
benefits of CVD screening during TB CXR screening as a poten-
tially affordable public health intervention.5 23 Health messaging 
on prevention of NCDs through recommendations on diet, such 
as reduction of commercial sugar and high salt diet, could be 
considered for integration in such programmes.23
Non- TB- related respiratory pathology, including chronic 
respiratory diseases (CRD), was another significant finding in 
our cohort. In a Vancouver study in 1960s, three cases of signif-
icant previously unknown non- TB lung disease were identified 
for every new TB case; in our study, this figure was approxi-
mately 2:1.6 It should be noted that CXR alone has limited 
specificity for many of these conditions, especially in this cohort 
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where very limited clinical information was available. The diag-
noses of ‘non- specific airspace opacification’ and ‘interstitial 
pattern’ cover a range of possible pathologies, varying from 
incidental acute or chronic infective changes, not typical of TB, 
to non- infective pathology. COPD and emphysema cannot be 
diagnosed reliably on CXR alone, requiring spirometry and 
referral for further confirmation. However, CRD morbidity and 
mortality is on the rise, with the prevalence of COPD shown to 
range between 4% and 25% in one systematic review in sub- 
Saharan Africa comparable to 3.6% (2.3%–4.4%) in our study.27 
As expected, our study confirmed that screening for TB will 
detect alternative lung abnormalities in a significant number of 
non- TB cases and spirometry as well as expert clinical review, for 
example, pulmonologists will be required for a subset of these 
patients.
Forty- four per cent of the participants in our study with 
reported post- TB lung changes had a history of TB treatment. 
Among those, CXR revealed bronchiectasis and/or destroyed 
lung in 11% (95% CI 3.3%–27.5%), which is lower than 
reported in a prospective study in Malawi, that used CT and 
reported >40% bronchiectasis and 10% lobar destruction 
post- TB treatment.20 Bronchiectasis has a lower detection rate 
on CXR than CT and will likely have been underestimated in 
our study. PTB is a risk factor for CRD and in the Malawi study 
ongoing clinical symptoms were associated with damage of three 
or more lobes,20 28 which is comparable to the ‘destroyed lung’ 
category in our CXR study. Unfortunately, patients with post 
TB lung disease (PTLD) and chronic symptoms are likely to be 
treated empirically for recurrent TB.29 We therefore recommend 
that TB screening programmes look into developing the area of 
PTLD further. Latent TB infection treatment should be offered 
to eligible patients with PTLD.30 Our study also identified other 
less common findings for which interventions may be costly. For 
example, mediastinal and lung masses/nodules (0.4%) that may 
represent lymphoma/ malignancy and would need referral for 
definitive diagnosis and management.
In our study, half the images reported as abnormal by the field 
clinical officers were subsequently reported by our radiologists 
as normal. This finding is not surprising as TB prevalence surveys 
by design encourage high sensitivity with field officers having a 
low threshold for identification of abnormalities and referral for 
sputum- based testing to maximise sensitivity in the initial prev-
alence survey screening stage.9 CAD software has been shown 
to have a role in TB screening activities especially prevalence 
surveys with diagnostic accuracy higher than clinical officers and 
comparable with expert radiologists.18 31 Inter- reader variability 
of CXR reporting is an acknowledged limitation and was also 
the case in our study with inter reader agreement moderate at 
0.41. This moderate agreement can be partly explained by the 
limited clinical information available to our reporting radiolo-
gists. Though CAD for TB software has an accuracy equal to 
expert readers, the software provides TB risk scores only. To 
characterise non- TB findings, once TB has been excluded, a 
human reader remains the only current solution available. CAD 
for cardiomegaly25 is under development and may provide an 
automated solution for the detection of cardiomegaly in the 
future.
Our study used population- based national prevalence data and 
an explicit sampling approach to select images for review. Each 
image was read by two expert radiologists. Moderate inter- reader 
variability was mitigated by applying a third reader to resolve 
discrepancies. However, low specificity is an acknowledged issue 
with radiological classification. This was a retrospective study 
and we had limited clinical information available. HIV results 
were self- reported. Important information such as smoking 
history and pre- existing medical conditions were not collected 
during the survey. We were therefore not able to adequately 
correlate clinical symptoms or HIV serostatus with our findings. 
Although the prevalence survey protocol required those with 
other CXR abnormalities to be linked to a health facility within 
the cluster, we had no way of ascertaining if this was done, or 
obtaining data on final diagnosis and clinical outcome.
CONCLUSION AND RECOMMENDATIONS
Our findings are strikingly similar to those of the 1940s study 
in Europe; that mass radiography can be used to tackle ‘funda-
mental problems of disease in the chest, both of the respi-
ratory system and also of the heart’ and ‘aid in detection of 
early and treatable non- TB disease’.5 Currently, TB screening 
activities using CXR and CAD software are focused on finding 
abnormalities consistent with TB.16 As countries embark on 
TB ACF activities, they need to be aware that other respira-
tory and non- respiratory pathologies are likely to be as, or 
more prevalent, than active TB. Mass screening with CXR 
therefore offers opportunity to plan for and address multiple 
important diseases.5 6 Even though the algorithms or protocols, 
for example, in TB prevalence surveys do recommend that any 
other abnormalities should be referred as appropriate, there 
is no structured system for the detection and referral of such 
patients.9 15 Clear referral pathways, diagnostics and follow- up 
plans for non- TB pathology could be incorporated during the 
planning of TB prevalence surveys and ACF activities.6 Prospec-
tive data collection about non- TB conditions identified during 
TB screening, characterisation of these patients, exploration 
of individual and health systems implications of these diseases 
could assist with further planning. Our findings were consistent 
with complications of potential underlying NCDs, including 
chronic respiratory disease in the population. At primary care 
health facilities, prevention efforts for NCDs could be strength-
ened including health messaging.
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